nci-h1650

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

ATG7-IN-1 is a highly potent, selective small-molecule ATG7 inhibitor with an IC₅₀ of 62 nM. ATG7-IN-1 blocks the formation of the ATG12-ATG5 and LC3-PE conjugate system at both the cellular and in vivo levels, thereby inhibiting autophagosome formation. ATG7-IN-1 can be used in research on autophagy mechanisms.

Sodium dichloroacetate (BCA) , a specific inhibitor of pyruvate dehydrogenase kinase (PDK) with IC50 values of 183 and 80 μM for PDK2 and PDK4 respectively, has been shown to derepress a mitochondrial potassium-ion channel axis, trigger apoptosis in cancer cells, and inhibit tumor growth.

4-Chloro-7-ethoxyquinoline (Compound 9a) is a quinoline derivative with anticancer properties. It effectively inhibits the proliferation of HCT-116, RKO, DLD1, HepG2, BGC-823, NCI-H1650, and SK-OV-3 cells, with IC50 values of 3.16, 3.87, 2.75, 2.66, 3.91, 3.34, and 3.46 μM, respectively.

Antitumor agent-209 (Compound 10g), a quinoline derivative, functions as an antineoplastic agent. It effectively inhibits the proliferation of various cancer cell lines, specifically HCT-116, RKO, DLD1, HepG2, BGC-823, NCI-H1650, and SK-OV-3, with IC50 values of 0.37, 0.58, 0.81, 0.79, 0.89, 0.78, and 0.89 μM, respectively.

20(R)-Ginsenoside Rg2 (20R-Ginsenoside Rg2) is a compound with anti-oxidant and anti-apoptosis.

20(R)-Ginsenoside Rg2 (Standard) is a reference standard for research and analysis in studies involving 20(R)-Ginsenoside Rg2. 20(R)-Ginsenoside Rg2 (20R-Ginsenoside Rg2) is a compound with anti-oxidant and anti-apoptosis.